During a Case-Based Roundtable® event, Andrew Yee, MD, discussed the use of carfilzomib-based regimens compared with other ...
Francis P. Worden, MD, discusses future plans to investigate combination therapies and other novel treatments in the thyroid ...
The FDA has accepted and granted priority review to tab-cel, a treatment for Epstein Barr virus-positive posttransplant ...
Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus ...
The FDA has granted 7MW3711 an orphan drug designation (ODD) for the treatment of small cell lung cancer (SCLC). 7MW3711 is a ...
Mazyar Shadman, MD, MPH, describes his clinical approach to treating patients with high-risk CLL/SLL, including those with or without del(17p) or TP53 mutations.
Findings from the phase 3 ARANOTE trial demonstrated an improvement in radiographic progression-free survival with darolutamide vs placebo plus androgen deprivation therapy in metastatic ...
During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and ...
Barbara O'Brien, MD, discusses the goals and results of a study investigating tucatinib, trastuzumab, and capecitabine for ...
The FDA has granted a rare pediatric disease designation to SLS009 for treating pediatric acute myeloid leukemia.
A dendritic cell vaccine called DOC1021 shows early promise in treating pancreatic cancer and has received a fast track ...
Please briefly discuss the latest results from the SEQUOIA Arm D trial, evaluating zanubrutinib plus venetoclax in treatment-naïve patients with CLL and del(17p) and/or TP53 mutations. How does the ...